- $1.56bn
- $1.29bn
- $16.10m
FDA official says UniQure fell short on Huntington's trial, defends new study request
Street View: Tough path ahead for uniQure after FDA setback on Huntington's therapy
UniQure tumbles after FDA says brain disorder therapy data insufficient, seeks new trial
Brief: Uniqure Provides Regulatory Update On Amt-130 For Huntington’S Disease
UniQure tumbles after FDA says brain disorder therapy data insufficient, seeks new trial
FDA tells uniQure early trial data insufficient for brain disorder therapy filing (updated)
FDA tells UniQure study data insufficient for brain disorder therapy application
UniQure falls after FDA commissioner comments
UniQure rises as US FDA review talks revive hopes for Huntington's therapy
Brief: Uniqure Provides Regulatory Update On Amt-130 For Huntington’S Disease
UniQure slides after FDA says inadequate clinical data for Huntington's therapy
UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy (updated)
FDA says clinical data for UniQure's Huntington's disease therapy not adequate
ClearPoint Neuro adds to gains, up 125% since Sept 23
UniQure eases after increased $300 mln equity offering
Brief: Uniqure Prices Public Offering Of 5,789,473 Shares At $47.50 Per Share
UniQure extends eye-watering rally ahead of planned $200 mln share offering
Brief: Uniqure Announces $200 Million Proposed Public Offering
UniQure launches $200 mln equity offering after shares skyrocket